{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"}],"units":"Participants"}],"description":"Estimated through the Kaplan-Meier method.","groups":[{"description":"CONCURRENT PHASE: Patients undergo fractionated stereotactic radiosurgery QD every weekday for 10 days and receive alisertib PO BID concurrently with radiation therapy for 10 days.\n\nMAINTENANCE PHASE: Patients receive alisertib PO BID on days 1-7. Treatment repeats every 21 days for up to 18 courses in the absence of disease progression or unacceptable toxicity.\n\nHyperfractionated radiation therapy: Undergo hyperfractionated radiation therapy\n\nStereotactic radiosurgery: Undergo stereotactic radiosurgery\n\nAlisertib: Given PO\n\nQuality-of-life assessment: Ancillary studies","id":"OG000","title":"Alisertib, Fractionated Stereotactic Radiosurgery"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"At 6 months","title":"Number of Participants With Overall Survival at 6 Months","type":"SECONDARY","unitOfMeasure":"Participants"}